Doxazosin mesylate

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Doxazosin mesylate
Generic name: DOXAZOSIN MESYLATE
Manufacturer: Chartwell RX, LLC
Product type: HUMAN PRESCRIPTION DRUG
SPL set ID: a7f589b0-eebb-48cb-912f-a4bd956e4dcb
SPL ID: fdb507a5-0211-0689-e053-6394a90a860a
Version: 1
Effective date: 2023-06-09
Source export date: 2026-09-28
Source partition: 9
Source file: https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/6784607726c827491ceaeab30d843632e0660ee8008c535197be5ed9e1e52201/drug-label-0009-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 06:03:27

Harmonized routes table
Harmonized routes
ORAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 24 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application applno	ANDA	075646	derived:openfda.application_number
application number		ANDA075646	openfda.application_number
brand name		Doxazosin mesylate	openfda.brand_name
generic name		DOXAZOSIN MESYLATE	openfda.generic_name
manufacturer name		Chartwell RX, LLC	openfda.manufacturer_name
ndc	package	62135-053-90	openfda.package_ndc
ndc	package	62135-051-90	openfda.package_ndc
ndc	package	62135-054-90	openfda.package_ndc
ndc	package	62135-052-90	openfda.package_ndc
ndc	product	62135-051	openfda.product_ndc
ndc	product	62135-052	openfda.product_ndc
ndc	product	62135-054	openfda.product_ndc
ndc	product	62135-053	openfda.product_ndc
ndc11	package	62135005190	derived:openfda.package_ndc
ndc11	package	62135005390	derived:openfda.package_ndc
ndc11	package	62135005490	derived:openfda.package_ndc
ndc11	package	62135005290	derived:openfda.package_ndc
rxcui		197625	openfda.rxcui
rxcui		197628	openfda.rxcui
rxcui		197626	openfda.rxcui
rxcui		197627	openfda.rxcui
spl id		fdb507a5-0211-0689-e053-6394a90a860a	id
spl set id		a7f589b0-eebb-48cb-912f-a4bd956e4dcb	set_id
unii		86P6PQK0MU	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Postural hypotension with or without syncope may occur. ( 5.1 ) Risk of Intraoperative Floppy Iris Syndrome during cataract surgery. ( 5.2 ) Screen for the presence of prostate cancer prior to treatment for BPH and at regular intervals afterwards. ( 5.3 )

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most commonly reported adverse reactions from clinical trials are Fatigue, malaise, hypotension, and dizziness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Chartwell RX, LLC. at 1-845-232-1683 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.